-
1 .
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
- 저자
- by Paula, Cramer; Moritz, Fürstenau; Sandra, Robrecht; Adam, Giza; Can, Zhang, et al.
- 소스
- The Lancet Haematology. 9:e745-e755